These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 28280103)

  • 1. Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
    Li XG; Ma N; Sun SS; Xu Z; Li W; Wang YJ; Yang X; Miao ZR; Zhao ZG
    Postgrad Med J; 2017 Sep; 93(1103):555-559. PubMed ID: 28280103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.
    Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW
    J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
    Wu Z; Liu AF; Zhou J; Zhang Y; Wang K; Li C; Qiu H; Jiang WJ
    J Neurointerv Surg; 2019 Apr; 11(4):352-356. PubMed ID: 30100558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of thrombelastographic parameters with post-stenting ischemic events.
    Wang B; Li XQ; Ma N; Mo D; Gao F; Sun X; Xu X; Liu L; Song L; Li XG; Zhao Z; Zhao X; Miao ZR
    J Neurointerv Surg; 2017 Feb; 9(2):192-195. PubMed ID: 26041100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
    Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
    J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?
    Bliden KP; DiChiara J; Tantry US; Bassi AK; Chaganti SK; Gurbel PA
    J Am Coll Cardiol; 2007 Feb; 49(6):657-66. PubMed ID: 17291930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
    Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
    Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes.
    Jeong YH; Bliden KP; Shuldiner AR; Tantry US; Gurbel PA
    Thromb Haemost; 2014 Apr; 111(4):713-24. PubMed ID: 24336898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
    Rao Z; Zheng H; Wang F; Wang A; Liu L; Dong K; Zhao X; Cao Y; Wang Y
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2074-2081. PubMed ID: 28736132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting.
    Gurbel PA; Bliden KP; Guyer K; Aggarwal N; Tantry US
    Thromb Res; 2007; 119(5):563-70. PubMed ID: 16806409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of VerifyNow P2Y12 and thrombelastography for assessing clopidogrel response in stroke patients in China.
    Lv HH; Wu S; Liu X; Yang XL; Xu JF; Guan YT; Dong Q; Zheng SL; Jiang JM; Li SX; Luo Z; Li L; An LX; Han Y
    Neurol Sci; 2016 Feb; 37(2):277-82. PubMed ID: 26520845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of PON1, P2Y12 and COX1 with Recurrent Ischemic Events in Patients with Extracranial or Intracranial Stenting.
    Li XQ; Ma N; Li XG; Wang B; Sun SS; Gao F; Mo DP; Song LG; Sun X; Liu L; Zhao XQ; Wang YL; Wang YJ; Zhao ZG; Miao ZR
    PLoS One; 2016; 11(2):e0148891. PubMed ID: 26870959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device.
    McTaggart RA; Choudhri OA; Marcellus ML; Brennan T; Steinberg GK; Dodd RL; Do HM; Marks MP
    J Neurointerv Surg; 2015 Jun; 7(6):425-30. PubMed ID: 24739599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
    Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
    Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction.
    Zhang JH; Tang XF; Zhang Y; Wang J; Yao Y; Ma YL; Xu B; Gao RL; Gao Z; Chen J; Song L; Wu Y; Meng XM; Yuan JQ
    Thromb Res; 2014 Nov; 134(5):970-5. PubMed ID: 25217066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.
    Xie C; Ding X; Gao J; Wang H; Hang Y; Zhang H; Zhang J; Jiang B; Miao L
    Pharmacogenet Genomics; 2014 Apr; 24(4):204-10. PubMed ID: 24535487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
    Koh JS; Park Y; Tantry US; Ahn JH; Kang MG; Kim K; Jang JY; Park HW; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA; Jeong YH
    Platelets; 2017 Mar; 28(2):187-193. PubMed ID: 27560946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
    Cotton JM; Worrall AM; Hobson AR; Smallwood A; Amoah V; Dunmore S; Nevill AM; Raghuraman RP; Vickers J; Curzen N
    Cardiovasc Ther; 2010 Jun; 28(3):139-46. PubMed ID: 20406238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.
    Bouman HJ; Harmsze AM; van Werkum JW; Breet NJ; Bergmeijer TO; Ten Cate H; Hackeng CM; Deneer VH; Ten Berg JM
    Heart; 2011 Aug; 97(15):1239-44. PubMed ID: 21628721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
    Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
    Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.